Nivolumab and pembrolizumab as immune-modulat- ing monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Expert review of anticancer therapy. 2015; 15(9):981-93. doi: 10.1586/14737140.2015.1074862 PMID: 26313415Faghfuri E, Faramarzi MA, Nikfar S, Abdollahi M. Nivolumab and ...
与接受Ipilimumab治疗的患者相比,接受Nivolumab治疗的患者接受后续免疫疗法的几率较低,分别为26%和36%。港安健康国际医疗介绍,在Nivolumab治疗组,患者继续接受Nivolumab(13%)、pembrolizumab(Keytruda;7%)、Ipilimumab(16%)、Ipilimumab+Nivolumab(6%)、Ipilimumab+pembrolizumab(<1%)、BRAF抑制剂(16%)、MEK/NRAS抑制剂(14%...
In advanced melanoma, immune-related responses have been observed in approximately 10% of patients treated with ipilimumab (anti–cytotoxic T-lymphocyte antigen 4),5 and in approximately 7% to 9% of patients treated with nivolumab or pembrolizumab (anti–programmed cell death receptor 1 [...
在nivolumab+ipilimumab组,1例PD,1例再次支气管镜检查时隆突肿瘤累及,认为不能再切除,1例因肺灌注不足和主动吸烟而被认为有很高的手术风险,1例拒绝手术。在两名接受非试验手术的患者中,一名IIIA期患者在服用三剂nivolumab后出现新的纵隔受累的放射学进展,治疗改为铂双联化疗+培布罗珠单抗(Pembrolizumab Off Trial)。
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma Background The anti-programmed cell death-1 (PD-1) inhibitors pembrolizumab and nivolumab alone or in combination with ipilimumab have shown improved objec... L Zimmer,S Apuri,Z Eroglu,....
Advances in immunotherapy for melanoma IpilimumabMelanomaNivolumabPembrolizumabIn recent years, the introduction and Federal Drug Administration approval of immune checkpoint inhibitor antibodies has ... JM Redman,GT Gibney,MB Atkins - 《Bmc Medicine》 被引量: 55发表: 2016年 Risk of elevated transaminases...
Response was ongoing in 9% of patients on ipilimumab (100% of responders) vs 12% of patients on the combination (42% of responders). Post-progression therapy for patients from both arms included pembrolizumab (Keytruda; n = 6; 8%), a PD-1 inhibitor (n = 5; 6%), ipilimumab (n...
1-4 The PD-1 axis inhibitors pembrolizumab and atezolizumab have additionally been approved for use as first-line monotherapy in patients with advanced NSCLC expressing programmed death-ligand 1 (PD-L1) or in combination with chemotherapy regardless of tumor PD-L1 expression.5-11 Ipilimumab is an...
References[1] Anthony V Serritella, Niraj K Shenoy. “Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis.” Jama Oncology (2023): 1441–1446. [2] Jonathan Ho, C. Kelly, Erick A. Argueta. “S3644 Nivolumab-Induced Liver Injury.” American...
At extended follow-up, nivolumab monotherapy showed improved disease-free survival, non-urothelial tract recurrence-free survival, and disease-specific survival vs placebo in patients with resected, high-risk muscle-invasive urothelial carcinoma.